One of the most remarkable aspects of the past half-decade has been a complete lack of change. Year... Read More

One of the most remarkable aspects of the past half-decade has been a complete lack of change. Year after year, the economy grew at a subpar pace, inflation remained subdued and stocks have bounded... Read More

$40? $50? $60? Nobody really knows where the price of oil will stabilize in coming quarters.... Read More

$40? $50? $60? Nobody really knows where the price of oil will stabilize in coming quarters. #-ad_banner-#And the eventual upturn? Supply destruction is taking place right now, which will eventually... Read More

I have a relative, who is well into her 70’s, and she absolutely loves stocks. Can’t... Read More

I have a relative, who is well into her 70’s, and she absolutely loves stocks. Can’t get enough of them. Any other asset class is simply too boring. #-ad_banner-#But she’s making a... Read More

An old investing maxim suggests that “as goes January, so goes the year.” And when you... Read More

An old investing maxim suggests that “as goes January, so goes the year.” And when you consider that the major indices wobbled sideways in January, seemingly ending a multi-year uptrend,... Read More

When Jonas Salk introduced a vaccine for the polio virus in 1957, scientists widely assumed that... Read More

When Jonas Salk introduced a vaccine for the polio virus in 1957, scientists widely assumed that cures would soon be found for many other common but lethal ailments. Yet, nearly six decades later,... Read More

Now is the time to invest in the housing market, but you must be selective. As my colleague Ian... Read More

Now is the time to invest in the housing market, but you must be selective. As my colleague Ian Floyd recently noted, the collapse in oil prices will bring renewed pressure to homebuilders,... Read More

Biotech stocks had a banner year in 2014. Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), Avanir... Read More

Biotech stocks had a banner year in 2014. Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), Avanir Pharmaceuticals, Inc. (Nasdaq: AVNR) and OvaScience, Inc. (Nasdaq: OVAS), for example, each rose roughly... Read More

Thanks to the sharp pullback in bond yields in recent months, focus is shifting back to their... Read More

Thanks to the sharp pullback in bond yields in recent months, focus is shifting back to their counterpart in the equities sphere: dividend stocks. Investors can now choose from solid, yet... Read More

  Across a wide range of industries, a combination of dividend increases and shareholder... Read More

  Across a wide range of industries, a combination of dividend increases and shareholder buyback programs has led this to be the “era of shareholder perks.” #-ad_banner-#As I... Read More

As part of our multi-part series about dividend stocks, we are taking a comprehensive look at the... Read More

As part of our multi-part series about dividend stocks, we are taking a comprehensive look at the wide range of dividend strategies that investors are currently deploying. For example, in part two of... Read More